ANGO vs. ATEC, OFIX, SRDX, ARAY, RMTI, RSLS, ABT, ISRG, BSX, and SYK
Should you be buying AngioDynamics stock or one of its competitors? The main competitors of AngioDynamics include Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), and Stryker (SYK). These companies are all part of the "health care equipment" industry.
AngioDynamics vs.
AngioDynamics (NASDAQ:ANGO) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.
AngioDynamics has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
AngioDynamics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
AngioDynamics currently has a consensus price target of $13.00, suggesting a potential upside of 27.70%. Alphatec has a consensus price target of $17.67, suggesting a potential upside of 71.19%. Given Alphatec's higher probable upside, analysts clearly believe Alphatec is more favorable than AngioDynamics.
AngioDynamics received 35 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 61.19% of users gave AngioDynamics an outperform vote while only 57.99% of users gave Alphatec an outperform vote.
Alphatec has a net margin of -31.06% compared to AngioDynamics' net margin of -79.38%. AngioDynamics' return on equity of -7.26% beat Alphatec's return on equity.
89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 66.3% of Alphatec shares are held by institutional investors. 5.4% of AngioDynamics shares are held by company insiders. Comparatively, 22.8% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Alphatec had 6 more articles in the media than AngioDynamics. MarketBeat recorded 9 mentions for Alphatec and 3 mentions for AngioDynamics. Alphatec's average media sentiment score of 1.29 beat AngioDynamics' score of 1.03 indicating that Alphatec is being referred to more favorably in the news media.
Summary
Alphatec beats AngioDynamics on 10 of the 18 factors compared between the two stocks.
Get AngioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AngioDynamics Competitors List
Related Companies and Tools
This page (NASDAQ:ANGO) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy ANGO Stock Free ANGO Stock Alerts